Who Paid My Doc
A Phase III, Open-Label, Randomized, Controlled, Multi-Country Study T
Research payments
$7,193,276
Through program year 2025, $7,193,276 in research payments was reported against A Phase III, Open-Label, Randomized, Controlled, Multi-Country Study T, across 476 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $551,462 | 85 |
| 2024 | Research | $1,040,256 | 232 |
| 2023 | Research | $5,601,558 | 159 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Patrick Dennis New Orleans, LA Named on 24 payments
- Mark Koch Fort Worth, TX Named on 19 payments
- Bruce Rankin Deland, FL Named on 18 payments
- Kathleen Jones West Des Moines, IA Named on 18 payments
- Abram Burgher Sun City, AZ Named on 18 payments
- Mira Baron West Palm Beach, FL Named on 18 payments
- Rica Santiago North Charleston, SC Named on 14 payments
- Ronald Surowitz Jupiter, FL Named on 13 payments
- Jara McDonald San Antonio, TX Named on 12 payments
- Antoinette Pragalos Cincinnati, OH Named on 12 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.